Engineered protein from flesh-eating bacteria acts as molecular 'superglue'

NewsGuard 100/100 Score

In a classic case of turning an enemy into a friend, scientists have engineered a protein from flesh-eating bacteria to act as a molecular "superglue" that promises to become a disease fighter. And their latest results, which make the technology more versatile, were the topic of a report here today at the 245th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society.

"We've turned the tables and put one kind of flesh-eating bacterium to good use," said Mark Howarth, Ph.D., who led the research. "We have engineered one of its proteins into a molecular superglue that adheres so tightly that the set-up we used to measure the strength actually broke. It resists high and low temperatures, acids and other harsh conditions and seals quickly. With this material we can lock proteins together in ways that could underpin better diagnostic tests - for early detection of cancer cells circulating in the blood, for instance. There are many uses in research, such as probing how the forces inside cells change the biochemistry and affect health and disease."

Howarth's team at the University of Oxford in the United Kingdom genetically engineered the glue from a protein, FbaB, that helps Streptococcus pyogenes (S. pyogenes) bacteria infect cells. S. pyogenes is one of the microbes that can cause the rare necrotizing fasciitis, or flesh-eating bacteria syndrome, in which difficult-to-treat infections destroy body tissue.

They split FbaB into two parts, a larger protein and a smaller protein subunit, termed a peptide. Abbreviating S. pyogenes as "Spy," they named the small peptide "SpyTag" and the larger protein "SpyCatcher." The gluing action occurs when SpyTag and SpyCatcher meet. They quickly lock together by forming one of the strongest possible chemical bonds. SpyCatcher and SpyTag can be attached to the millions of proteins in the human body and other living things, thus gluing proteins together.

In an advance reported at the meeting, Howarth described how Jacob Fierer, a graduate student on the research team, greatly reduced the size of the SpyCatcher part of the technology. That achievement makes the technology more flexible, enabling scientists to connect proteins into new architectures, he said.

One of the applications on the horizon involves testing the technology as a new way to detect "circulating tumor cells," or CTCs. Tumors shed these cells into the bloodstream, where they may act as seeds, spreading or metastasizing cancer from the original site to other parts of the body. That spreading is the reason why cancer is such a serious health problem. Detecting CTCs is an active area of research worldwide because of its potential for early diagnosis of cancer - from blood samples rather than biopsies - and determining when new treatments may be needed to prevent the disease from spreading.

Howarth said that the Spy technology has advantages over other molecular gluing systems that are available. SpyCatcher and SpyTag, for instance, can glue two proteins together at any point in the protein. "That flexibility allows us many different ways to label proteins and gives us new approaches to assemble proteins together for diagnostic tests," Howarth explained.

Howarth and colleagues are working with Isis Innovation, the University of Oxford's technology transfer company, to find potential partners to bring the Spy system to the market.

Source American Chemical Society

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals deadly bacteria's attraction to human blood